Paediatric clinical trials need paediatric clinical trial budgets.
budget
clinical trials
medicines for children
paediatrics
Journal
Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
25
04
2023
received:
05
03
2023
accepted:
27
04
2023
medline:
10
8
2023
pubmed:
29
4
2023
entrez:
29
4
2023
Statut:
ppublish
Résumé
Clinical trials and the need for new treatments were recently listed among the most important factors for child health. The aim of the present study was to describe some of our experiences with budget preparations in paediatric clinical trials. We selected 10 trials sponsored by the pharmaceutical industry at the Pediatric Clinical Research Center at Sahlgrenska University Hospital in Gothenburg, Sweden. We compared the sponsor's initial budget (budget proposal from the sponsor), with the final budget (negotiated and agreed between sponsor and site) and identified areas where discrepancies may arise. The mean difference in total budget amount between the initial budget and the final budget was +60% (mean 59%, range 31%-139%). The costs for preparation of the clinical trial, time spent for study activities and costs for examinations were identified as key budget items for these differences. Our findings indicate that a substantial part of the trial-related costs would not be covered by the sponsor, had the initial budget been accepted. A thorough review and budget negotiation, as well as to have a dedicated team member for this task, are essential to ensure equitable responsibility for the study-related costs and to avoid discontinuation of trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1982-1985Subventions
Organisme : ALF Västra Götalandsregion
ID : ALFGBG-965996
Organisme : Hjärt-Lungfonden
ID : 20220406
Organisme : Hjärt-Lungfonden
ID : 20220620
Organisme : Vetenskapsrådet
ID : 2021-01439
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 The Authors. Acta Paediatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Paediatrica.
Références
Naumburg E, Rane A, Halvorsen T, et al. Tardy development of safe medicines for children: a Nordic network offers new platform to reduce this inequity. Acta Paediatr. 2019;108(6):992-993.
Rocchi F, Tomasi P. The development of medicines for children. Part of a series on pediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res. 2011;64(3):169-175.
Lagler FB, Hirschfeld S, Kindblom JM. Challenges in clinical trials for children and young people. Arch Dis Child. 2021;106(4):321-325.
Bourgeois FT, Kesselheim AS. Promoting pediatric drug research and labeling - outcomes of legislation. N Engl J Med. 2019;381(9):875-881.
Hirschfeld S, Lagler FB, Kindblom JM. Prerequisites to support high-quality clinical trials in children and young people. Arch Dis Child. 2020;106:423-428.
Owens B. The push to improve children's health. Nature. 2022;612(7941):S41.
Kindblom JM, Kjellen T, Finizia C, Milsom I, Mellgren K. The convention on the rights of the child (UNCRC) and its implementation in paediatric clinical research. Acta Paediatr. 2020;109(12):2454-2458.
Sahlgrenska Universitetssjukhuset. Slutrapport. Utredning om möjligheten att etablera en gemensam stödstruktur för klinisk forskning vid Drottning Silvias Barn- och Ungdomssjukhus i Göteborg. SU2020-01804. 2014.
Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics. 2016;138(3):e20160223.